The Healthcare Short Sales That Never Fit TheStreet.com Johnson & Johnson's(JNJ) Orthoclone OKT3 (known chemically as muromonab) received FDA approval in 1986 for the prevention of acute transplant rejection, but the technology relied solely on mouse protein. The resulting risk of autoimmune rejection of ... |
